Overview
INJ and USDAT rarely move in perfect sync. Today’s print ($4.98/$1,853.59) and 24h leaders (Injective) help frame which side currently carries relative strength.
Quick winners
Full comparison
| Metric | INJ | USDAT |
|---|---|---|
| Price | $4.98 | $1,853.59 |
| Market Cap | $490.41M | $106.95M |
| FDV | — | — |
| Volume 24h | $2.75M | $1.94M |
| Circulating Supply | — | — |
| Total Supply | — | — |
| Max Supply | — | — |
| Rank | 99.00 | 247.00 |
| Dominance | — | — |
| Liquidity | — | — |
| Volatility | +5.97% | +3.64% |
| ATH | — | — |
| ATL | — | — |
| ROI | — | — |
Performance
| Timeframe | INJ | USDAT |
|---|---|---|
| 1H | — | — |
| 24H | +1.20% | +0.00% |
| 7D | — | — |
| 30D | — | — |
| 90D | — | — |
| 1Y | — | — |
| YTD | — | — |
| ALL | — | — |
Comparative chart
Technical indicators
| Indicator | INJ | USDAT |
|---|---|---|
| RSI | 49.29 | 49.02 |
| MACD histogram | — | — |
| EMA20 | — | — |
| EMA50 | — | — |
| EMA100 | — | — |
| EMA200 | — | — |
| SMA50 | — | — |
| SMA200 | — | — |
| ATR | 0.29 | 67.35 |
| ADX | 12.19 | 21.33 |
| Support | 4.91 | 1,827.82 |
| Resistance | 5.07 | 1,960.30 |
| Trend | neutral | bearish |
| Momentum | — | 67.00 |
| Signal | neutral | neutral |
Automatic technical analysis
Automated technical notes for this pair highlight neutral conditions on INJ and bearish on USDAT. Volatility differences can amplify short-term gaps.
Fundamentals
| Metric | INJ | USDAT |
|---|---|---|
| Consensus | — | — |
| Blockchain | — | — |
| TPS | — | — |
| Block time | — | — |
| Finality | — | — |
| Validators | — | — |
| Staking | — | — |
| TVL | — | — |
| Supply model | — | — |
| Inflation | — | — |
| Developer activity | 0.00 | — |
| Github activity | 118.00 | — |
| On-chain activity | — | — |
| Whale activity | — | — |
| Addresses | — | — |
| Gas fees | — | — |
Ecosystem
Injective
USDAT
Pros and cons
Pros of Injective
- Market-cap scale on Injective may dampen some idiosyncratic shocks versus smaller peers.
- INJ often anchors narratives that attract sustained media and analyst coverage.
- Higher ranking for Injective can translate into tighter spreads on major venues.
- Injective typically benefits from deeper liquidity and broader market recognition inside the Top 300 set.
Cons of Injective
- Data gaps in niche fundamentals still apply — absence of a field is not confirmation.
- Large-cap status for Injective can mean slower percentage upside versus high-beta alternatives.
- Crowded positioning around INJ sometimes amplifies squeeze or flush risk.
Pros of USDAT
- If technical momentum aligns, USDAT may outperform on medium-term windows.
- USDAT can offer higher relative beta when market attention rotates toward its niche.
- Active volume bursts on USDAT sometimes precede sharper tactical moves.
- PEPS tracking for USDAT still includes AI score and level context for monitoring.
Cons of USDAT
- Higher volatility on USDAT cuts both ways and demands stricter risk limits.
- Incomplete fundamental coverage can hide operational or tokenomic risks.
- Weaker market-cap standing may leave USDAT more exposed to liquidity droughts.
- Relative underperformance versus Injective can persist through entire market regimes.
Which looks stronger right now?
Across winners above, no single coin dominates every column. Prefer scenarios: trend continuation favors the side with aligned momentum; mean-reversion favors the side stretched on RSI.
AI summary
In about three hundred words of context: Injective (INJ) trades near $4.98 with a +1.20% day move, while USDAT (USDAT) is around $1,853.59 (+0.00%). Volume leadership currently sits with Injective, and market-cap leadership with Injective. Technical trend labels read neutral vs bearish, with RSI near 49.29/49.02. Bottom line: use this page as a structured checklist, then open each coin page and related PEPS tools before acting. Nothing here is financial advice.
FAQ
Which is better, Injective or USDAT?
“Better” depends on horizon and risk. Injective leads on market cap today, while Injective leads the 24h move — neither is a guarantee.
Which has more upside potential, INJ or USDAT?
Higher-beta assets can move more in both directions. Use performance tables and volatility, not headlines, to judge potential ranges.
Which is less risky right now?
Lower volatility and deeper liquidity usually imply milder path risk, but crypto tails remain large for both Injective and USDAT.
Which has stronger developer activity?
Check the fundamentals table for developer/github fields when populated. Missing values mean the feed has no reliable reading yet.
Which looks more decentralized?
Decentralization is multi-dimensional (validators, client diversity, token distribution). This page surfaces available consensus/validator fields without over-claiming.
Which has lower fees?
Fee comparisons belong to each network’s fee market. Where gas/fee metrics exist in fundamentals, compare them; otherwise verify on explorers.
Which is better for investing?
Investing choices need personal constraints. Use this comparison as research input, then size positions with an explicit invalidation plan.
Which is better for staking?
If staking fields are present, compare yield mechanics and lockups off-platform. Staking returns are not risk-free.
Which is more used day to day?
Volume, on-chain activity and ecosystem links are practical usage proxies. Injective currently leads traded volume on this snapshot.
Which has the better recent performance?
See the performance table across 1h through 1y. The 24h leader is Injective, but longer windows can disagree.